The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Would be good if PYC gets involved with this.
Immune cells hunt down cancer around the body – discovery could lead to personalised treatments for advanced breast cancer
https://www.icr.ac.uk/news-archive/immune-cells-hunt-down-cancer-around-the-body-discovery-could-lead-to-personalised-treatments-for-advanced-breast-cancer
I am sure JM will remain committed to the success of PYC. He holds 1.9m shares and has options on a further 1.9m shares
The role /expansion was explained in presentation November I think
Ie wanted someone full time and IN HOUSE
Firstly would help if Dr Peter responded to Investors emails.....very unprofessional Dr Jim Millen always did.
In regards to Head Of Modelling - I believe this frankly is because Dr Mistry isnt doing the work any more as himself and Dr Millen are setting up another business and working else where - as per companies house.... This has always been in the pipeline for many years now... there business has just been given some more investment i believe
We are now around four months into Peter Sargent's time at the helm. All the key initiatives that are currently work-in-progress - DosemeRx, Beyond Blood, Bio-statistics and also the numerous major contract relationships - result from JM's time as CEO
Under Peter's leadership we have had the move to appoint an in-house 'Head of Modelling' and a deliberate drive towards attending more conferences/events with a view to growing the reputation of the company within the industry and its pipeline. No doubt he will be working hard behind the scenes on new initiatives in order to make his mark and take the company to another level
I believe there are exciting times ahead
Can’t do any work without any staff????
Trench with respect now is not the time . They have responses and feed back from 2 conferences that no doubt they will be addressing and are working on signing off two contracts that will form a major element / backbone of next years trading. There after we should receive more information on their pipeline. I know its a far better feeling to see the share price moving up but as others have said a little patience is required at moment and I totally agree. My average is approximately 1.38 and I am happy to continue buying sub 2p on information currently to hand. Once they publish news of progress I will re-evaluate this. As I have said previously the opportunities are out there and PYC is well placed to address them.
Emailed Dr Peter a few weeks ago - zero response
Ant, it would be great if you could try again to have dialogue with PYC. I have no doubt that Peter Sargent would be very receptive to any comments and suggestions you have for progressing the business
I agree with you but you must remember that some of us have been invested for over 20 years. The FDA's requirements for insilico prediction are very welcome but the company does need to pursue its objectives and advantage itself of their Act ( Dec 22 ). and not let the grass grow under its feet. We have all acknowledged that personalised medicine is the way forward and that the company is in a position at long last to realise its potential . Time is actually of the essence in this respect PYC needs to ensure that its sales techniques are in line with current thought, the time to sit back and relax are long gone. Critically if the board cannot sell their technology they need someone that can! I am so supportive but need to see action not talk or intellectual debate. I am buying and will continue to do so but shareholders need action to ensure their faith is justified! ! There are a lot of M&A opportunities out there and similarly royalty shares for service PYC need to be flexible and innovative!!
From March 2024
A significant number of new client contracts are now originating from both scientific conferences (such as EORTC-NCI-AACR & AACR Annual Meeting) as well as more business focused meetings (such as BioEurope
Morning Carliol
They also completed 2 very large conference in April too ,would expect more business to come form there too
Hello Laura,
Patience is the key. The market cap is seriously under valuing PYC.
There are lots of prospective deals in the pipeline and I'm sure the San Diago conference will generate some new contacts and some new sales.
Carliol
DB it was genuinely impossible to buy for over two hours yesterday Then a flood of shares. I would not get too bothered about how the price fluctuates and have confidence that PYC are most certainly in a good shape at the right time in a sector that is occasioning tremendous interest. ant
It seems to be a not uncommon occurrence across AIM. I have always suspected small groups of traders working in unison for small margin gains. Another scenario is someone forward selling of placing shares (is it legal ?) but see no reason for this to be a factor here. Markets often makes no sense and can be very murky
For a few days recently i have read from posters like Laura and Ant that its has been difficult to buy shares of PYC with amounts of less than £1000 being hard to come by.
Then you get days like yesterday where there are some hefty sells and the price goes down, Was it still hard to buy yesterday with all these sells coming in? Why would it be difficult to buy large amounts? What is the point in this suppression of buying? Is this just the way of the market, or is it just down the the MM's ?
Thanks Trench
The FDA Centre of excellence looks very exciting
A few days ago PYC referenced a link to this recent article which suggests that 'Personalised Circadian Medicine Will Likely be a Game Changer in Oncology'
https://www.sciencedirect.com/science/article/pii/S2452310024000027
They have followed this up with a post yesterday which links to a detailed study carried out for AACR 2008 covering a Circadian Clock Model
https://www.physiomics.co.uk/wp-content/uploads/2019/04/Poster_AACR2008_no801_13April.pdf
Looks like PYC could be well positioned to take advantage of their specialist knowledge in this important area of research
Was appointed CMO in November of Oxford Cannabinoid Who have announced they delisting - wonder if his role will change / end???
FDA’s Center for Drug Evaluation and Research (CDER) announces new Quantitative Medicine Centre of Excellence
At Physiomics we have long understood the importance and application of quantitative medicine in the development of new therapeutic drugs. Over the years we have used this expertise to strengthen our clients’ evidence and understanding of their drugs’ behaviour, in both safety and efficacy, to de-risk their development journey.
By establishing the QM Centre of Excellence, an institute dedicated to application and development of quantitative modelling and simulation approaches, the FDA are recognising the need for this expertise in streamlining development of new therapeutic drugs.
The aim of the QM Center of Excellence is “to facilitate and coordinate the continuous evolution and consistent application of QM across CDER”.
Furthermore, this is another signal that the regulators are increasingly encouraging and expecting model-based evidence in regulatory applications and assessments. To learn more about Physiomics’ expertise in quantitative pharmacology and how this can be applied to de-risk decisions and make the development of your therapeutic pipeline more efficient, please get in touch!
Afternoon Carliol
At the current £1 7mln market capitalisation PYC is a very good buy
Morning All,
Looks like my modest top up has been the precursor to the 300,00 sell a few minutes later.
It's said in life there are only two certainties in life. Death and taxes. Now I'll add a third. Never follow my on the stock market.
I've traded shares for longer than I care to remember. I've always found it interesting but never boring.
Carliol
Car
Morning All,
This is my first post on the PYC
I first bought some shares two weeks ago and have managed to make a small top up today at 11.23 for 25,000 shares.
I found it impossible to make a normal buy with HL but managed to succeed with a fill and kill order at 1.39.
I'm looking forward to an interesting and profitable investment in PYC.
Carliol
Morning Ant
Yes,yesterday I put an order in and today I cannot buy at all